

1 **Mapping the common barriers to optimal COPD care in high and middle-income countries:**  
2 **qualitative perspectives from clinicians.**

3 Orjola Shahaj<sup>1</sup>; Anne Meiwald<sup>1</sup>; Krishnan Puri Sudhir<sup>1</sup>; Rupert Gara-Adams<sup>1</sup>; Peter Wark<sup>2</sup>; Alexis  
4 Cazaux<sup>3</sup>; Abelardo Elizondo Rios<sup>4</sup>; Sergey Avdeev<sup>5</sup>; Elisabeth J Adams<sup>1</sup>

5

6 <sup>1</sup>Aquarius Population Health, London, UK; <sup>2</sup>John Hunter Hospital, Australia; <sup>3</sup>Universidad Nacional de  
7 Cordoba, Argentina; <sup>4</sup>Autonomous University of Nuevo Leon, Mexico; <sup>5</sup>Sechenov First Moscow State  
8 Medical University, Russia

9 Correspondence: Dr Elisabeth J Adams

10 Aquarius Population Health, Unit 29 Tileyard Studios, London N7 9AH, UK

11 Tel +44 (0)207 993 2930

12 Email: [elisabeth.adams@aquariusph.com](mailto:elisabeth.adams@aquariusph.com)

13

14 Target journal: International Journal of COPD

15 Word count: 3864

16

17 **Background:** Although predominantly preventable and treatable, chronic obstructive pulmonary  
18 disease (COPD) is a leading cause of death globally. Guidelines for managing the condition are widely  
19 available, yet COPD care remains suboptimal in many settings, including high and middle-income  
20 countries (HICs and MICs). Several approaches are used to diagnose and manage COPD, resulting in  
21 substantial variation in its care pathways.

22 This study aimed to explore how barriers to optimal COPD care vary across HICs and MICs by  
23 identifying common and unique barriers to COPD care in six countries to inform global policy  
24 initiatives for better care while addressing specific challenges.

25 **Methods:** Based on international and national guidelines, we mapped COPD care pathways for  
26 Australia, Spain, Taiwan, Argentina, Mexico, and Russia. Country-specific pathways were populated  
27 with published epidemiological, health economic, and clinical data identified through a pragmatic  
28 literature review. Semi-structured interviews with 17 respiratory care clinicians further informed and  
29 validated the pathways, data inputs, and key issues arising in each country. Thematic content  
30 analysis was used to analyse common and unique barriers across countries.

31 **Results:** Six themes were common in most HICs and MICs: *“Challenges in COPD diagnosis”*,  
32 *“Strengthening the role of primary care”*, *“Fragmented healthcare systems and coordination*  
33 *challenges”*, *“Inadequate management of COPD exacerbations”*; *“Limited access to specialised care”*  
34 *and, “Impact of underfinanced and overloaded healthcare systems”*. One theme, *“Insurance*  
35 *coverage and reimbursement challenges”*, was more relevant for MICs.

36 HICs and MICs differ in patient and healthcare provider awareness, primary care involvement,  
37 spirometry access, and specialised care availability. Both face issues with healthcare fragmentation,  
38 guideline adherence, and COPD exacerbation management. MICs also grapple with resource  
39 limitations and healthcare infrastructure challenges.

40 **Conclusion:** Many challenges to COPD care are the same in both HICs and MICs, underscoring the  
41 pervasive nature of these issues. While country-specific issues require customised solutions, there  
42 are untapped possibilities for implementing global respiratory strategies that motivate countries to  
43 manage COPD effectively. In addition to healthcare system-level initiatives, there is a crucial need for  
44 political prioritisation of COPD to secure the essential resources it requires.

45

46 **Introduction**

47 Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterised by  
48 irreversible airflow limitation and symptoms such as dyspnoea, cough, and sputum production.  
49 Despite being preventable and treatable (1), according to the Global Burden of Disease Study, in  
50 2019, COPD accounted for 3.3 million deaths, globally (2). COPD is already the third leading cause of  
51 death globally, which is seven years ahead of the World Health Organisation's (WHO) prediction of  
52 2030 (3). By 2060, deaths from COPD are expected to rise to 5.4 million (4).

53 The highest age-standardised COPD prevalence is in high-income countries (HICs), where it persists  
54 as a significant public health issue due to the considerable healthcare, economic and societal burden  
55 (2). It is also an important issue in upper middle-income countries (UMICs) which are expected to  
56 experience an increasing burden of this disease as their economies grow and populations age (5).  
57 Moreover, compared to HICs, UMICs may have more limited resources to respond to increased  
58 demands on their health systems, including fewer healthcare facilities and limited availability of  
59 essential medications and technologies (6).

60 The Global Initiative for Obstructive Lung Disease (GOLD) provides guidance on a universal and  
61 standardised approach to COPD care (4). Despite this guidance being widely available, COPD is often  
62 suboptimally managed in practice, and guidelines are not followed (7–9). This is linked to variation in  
63 how COPD care is delivered between settings (10–12) and leads to heterogeneity in patient  
64 outcomes and quality of life (QoL) (13).

65 Currently, no well-established and widely recognised method exists for mapping practical aspects of  
66 care delivery to identify deviations from the guideline provisions. One approach is reported by  
67 Meiwald *et al.* for COPD Evidenced Care Pathways, which collated and illustrated the steps in  
68 delivering COPD care across four healthcare settings (14). The Evidenced Care Pathways were  
69 developed based on clinical guidelines, peer-reviewed articles, and clinician perspectives, providing a  
70 qualitative assessment of differences between clinical practice and guidelines.

71 A granular understanding of barriers to providing guideline-adherent care in COPD and how they  
72 differ across countries with diverse healthcare systems could provide useful insights for  
73 policymakers and healthcare providers. The insight could improve policy planning, effective resource  
74 allocation and the successful implementation of initiatives to improve care (15).

75 This study seeks to identify common and unique barriers preventing optimal COPD care in three HICs  
76 (Australia, Spain and Taiwan) and three UMICs (Argentina, Mexico and Russia) to better inform

77 global policy initiatives that tackle shared barriers (16) while ensuring that unique issues are  
78 addressed through more tailored approaches.

## 79 **Material and methods**

80 This study used a previously reported mixed-method approach (14) to generate Evidenced Care  
81 Pathways. A qualitative analysis of the clinician interviews was conducted to evaluate each country's  
82 themes. A narrative synthesis was used to compare themes in HICs and UMICs. The definition of  
83 HICs and UMICs was based on the World Bank classification (17).

84 **Development of Evidenced Care Pathways:** Pragmatic searches were conducted on PubMed and  
85 Google Scholar to identify: 1) international and national guidelines for the diagnosis and  
86 management of COPD and 2) economic, epidemiological and clinical data about COPD in the study  
87 settings. See Supplement 1 for the search strategy. The literature review findings informed the  
88 pathway mapping and the discussion guides for the clinician interviews.

89 Initially, a generic pathway outlining the steps to COPD care was drafted for each country based on  
90 the GOLD recommendations. It was further refined using country-specific guidelines (18–23). The  
91 pathways were then used as a visual aid in the clinician interviews to assess how current care  
92 delivery deviates from guideline provisions. Further changes to the pathways to reflect current care  
93 delivery were made following clinicians' input, using an iterative approach until the final structure of  
94 the Evidenced Care Pathway was achieved.

95 **Qualitative analysis of barriers to optimal COPD care:** Semi-structured interviews with 17 clinicians  
96 were used to develop and validate the structure of the COPD Evidenced Care Pathways and  
97 understand clinician-perceived barriers to optimal COPD care. The qualitative analysis followed the  
98 consolidated criteria for reporting qualitative research (COREQ) checklist (24).

### 99 *a) The research team and reflexivity*

100 A summary of the characteristics of the research team and their relationship with the participants is  
101 provided in Table 1.

### 102 *b) Participant selection*

103 A total of 39 potential participants were approached through an email invitation, and 17 agreed to  
104 participate in the study. The participants met the following criteria: 1) healthcare professionals  
105 (HCPs) working in Argentina, Australia, Mexico, Spain, Russia, or Taiwan at the time of the study; and  
106 2) who played an active role in diagnosing or managing COPD in any healthcare setting (primary,  
107 secondary or tertiary). Purposive sampling was used in all the countries. The choice of the countries  
108 was guided by the need to ensure diversity in geography and healthcare systems.

109        *c) Data collection*

110 Interviews took place between April – September 2021 online via Microsoft Teams<sup>®</sup>. Consent to  
111 participate, record and transcribe the interview was obtained in advance from all participants via  
112 email. Participants were informed of the estimated length of the discussion. An example of an  
113 interview discussion guide is provided in Supplement 2. Two interviewers were present in each call;  
114 a lead and a notetaker. An interpreter was present in three interviews. In these cases, only the  
115 English translation was transcribed. Seven interviews were conducted in Spanish (both interviewer  
116 and interviewee were native speakers), and certified translators later translated the transcripts into  
117 English for the thematic analysis. Transcripts were not returned to participants for correction. All  
118 participants consented to receive follow-up emails with clarifying questions regarding the Evidenced  
119 Care Pathways and were asked to validate the final structure. They were offered the option to  
120 receive an honorarium at the end of the process.

121        *d) Data analysis*

122 The interview data were analysed using deductive and inductive thematic analysis (25). Transcripts  
123 were coded using an existing framework (14). Data within each theme was then coded line by line to  
124 create sub-categories (inductive component). Particular attention has been paid to identifying both  
125 common and unique barriers. A note was made if the subtheme implied some form of improvement  
126 in COPD care. AS coded the transcripts. OS double-coded 20% of the data (four transcripts) (Table 1).  
127 Discrepancies were resolved through discussion. Results were anonymised before reporting.

128 A narrative synthesis was deployed to compare the themes and subthemes across the countries. A  
129 note was made where themes or subthemes were not applicable to a country and details of the  
130 country-specific nuances were captured separately.

131        **Ethics**

132 No personal or patient-specific information was collected during the interviews. Participants were  
133 asked questions regarding the healthcare services for COPD in their country. Therefore, the project  
134 was deemed a service evaluation, and no ethics approval or review was necessary. Any data  
135 collected before, during and after the interview was handled following the European Union's  
136 General Data Protection Regulation (GDPR) legislation.

137

## 138 **Results**

### 139 **Evidenced Care Pathways**

140 The detailed Evidence Care Pathways for Argentina, Australia, Mexico, Spain, Russia and Taiwan are  
141 presented in Supplement 2. Figure 1 shows an example of the overview page for an Evidenced Care  
142 Pathway. The pathways for all countries showed consistency in the organisation and care delivery  
143 for COPD. They split across patient touchpoints with the healthcare system over three key  
144 components: pre-diagnosis, diagnosis, and management.

145 However, differences between the Evidenced Care Pathways were observed. These are mainly  
146 related to how patients access specialist care, the tests used for COPD diagnosis, differences in the  
147 treatment algorithms, guidelines for managing COPD, and treatment reimbursement.

### 148 **Themes from qualitative analysis of interviews**

149 Seven themes were identified, covering barriers to COPD care across the six countries. Table 2 lists  
150 the universal primary themes, level two sub-themes, and quotes supporting them. Table 3 shows  
151 where there was variation between countries for the primary themes and pinpoints if there were  
152 country-specific nuances within the subthemes.

153 Tables 4–10 provide detail on the unique features observed in some settings within a given theme.

#### 154 Theme 1: Challenges in COPD diagnosis

155 Clinicians identified COPD diagnosis as a significant challenge affecting both patients and healthcare  
156 systems. Not having a COPD diagnosis hinders patients from entering the diagnostic pathway,  
157 leading to prolonged periods without treatment. Clinicians expressed concerns about the high  
158 prevalence of undiagnosed COPD cases, particularly in countries with a high prevalence of smoking  
159 or exposure to biomass fuels, such as Russia, Argentina, and Mexico.

160 Low awareness about COPD among patients was mentioned as a key factor leading them to adapt to  
161 or tolerate the disease without seeking proper medical attention. Clinicians observed that patients  
162 often presented with advanced stages of the disease, suggesting reasons such as delays in seeking  
163 healthcare, failure to consider COPD by clinicians, lack of spirometry to diagnose it and the lack of  
164 timely interventions.

165 *"But I think a substantial number of patients are undiagnosed in Taiwan, because (...) sometimes we see*  
166 *patients very advanced the COPD. (sic) They are not diagnosed before."* - Respiratory Specialist, Taiwan.

167 They also noted that COPD symptoms frequently went unrecognised during multiple visits to  
168 healthcare providers before a formal diagnosis was made. Most importantly, clinicians explained  
169 how exacerbations are often the driver for initiating the diagnosis process.

## 170 Theme 2: Strengthening the role of primary care in COPD

171

172 Clinicians emphasised the missed opportunities to enhance the role of primary care in improving  
173 COPD diagnosis. They expressed concerns about the limited consideration of COPD by primary care  
174 physicians (PCPs), who are typically patients' first point of contact. Difficulties differentiating COPD  
175 symptoms from other conditions, particularly asthma, were highlighted as contributing to  
176 misdiagnosis and underdiagnosis.

177 *"They even forget how [to interpret] lung function test[s] because they are more familiar with*  
178 *diabetes, more familiar with hypertension (...)",* Respiratory Specialist, Taiwan.

179 Clinicians also identified the lack of access and inconsistent use to spirometry, and PCPs' lack of  
180 confidence in interpreting results as significant barriers to timely COPD diagnosis.

181 Inconsistent use of spirometry in primary care settings adds to the diagnostic challenges, and  
182 subsequently, important bottlenecks are created in the system if patients rely only on respiratory  
183 specialists for diagnosis (Theme 3 and 4).

184

## 185 Theme 3: Fragmented healthcare systems and coordination challenges add to the 186 complexity of managing COPD

187

188 COPD management depends on various factors, including interactions between healthcare providers  
189 and patients, healthcare infrastructure availability, and access to treatment options. The healthcare  
190 services that COPD patients need are divided between primary care, specialists (in secondary care)  
191 and emergency departments. Clinicians reported that there is some disconnect between these  
192 services, often leaving patients without adequate management.

193 Clinicians emphasised the need for effective coordination between patients, primary care physicians,  
194 and specialists in managing the complex nature of COPD. They recognised opportunities for  
195 clarifying the roles of general practitioners (GPs) and specialists in treatment initiation and follow-  
196 up. GPs' lack of confidence and training in initiating treatment for mild cases was highlighted,  
197 reflecting missed opportunities for alleviating the excess burden on secondary care and reducing  
198 waiting times, which are important determinants in the patient journey (Theme 2, 5 and 7).

199 Poor understanding and adherence to pharmacological treatment guidelines were highlighted  
200 (mainly among PCPs but in some cases among specialists too). Clinicians expressed concerns about  
201 the inadequate understanding of treatment options among healthcare providers, leading to  
202 underusing or misusing pharmacological and non-pharmacological interventions.

203 *“70% of [of COPD patients] in Mexico aren’t receiving adequate treatment. Because there’s steroid*  
204 *overuse. Things are the other way around here... A COPD patient is given a bunch of steroids, and an*  
205 *asthma patient is given a bunch of SABA. Things are upside down.”* Respiratory Specialist, Mexico.

206 They acknowledged the impact of poor patient compliance, adherence, and self-management on  
207 treatment outcomes which they believed is sometimes linked to insufficient resources dedicated to  
208 patient education. Substantial variation in guideline adherence was reported, particularly among  
209 GPs (Theme 1, subtheme 4).

210

#### 211 Theme 4: Inadequate management of COPD exacerbations

212

213 Clinicians recognised the challenges in effectively managing COPD exacerbations. They observed  
214 frequent underreporting, delayed reporting, and misclassification of exacerbations.

215 *“I think that up to 40% of the exacerbations don’t even get to be seen by a specialised physician or at*  
216 *the emergency care unit..”,* Respiratory specialist, Argentina.

217 Inadequate notification systems and lack of information sharing between healthcare providers  
218 reportedly contributed to the ineffective management of exacerbations.

219 *“We are now doing some steps in this direction [setting up a notification system for exacerbations],*  
220 *but usually we know about the situation from our patient.”* – Respiratory Specialist, Russia.

221 Clinicians repeatedly emphasised the importance of patient education to enable early identification  
222 and appropriate response to exacerbations. They highlighted the need for action plans to be  
223 promptly set up or revised following exacerbations to optimise treatment outcomes. Discharged  
224 patients may not receive treatment reviews, further perpetuating the cycle of poor management.

225 Following discharge, patients reportedly need to wait a long time to see a specialist that can review  
226 their treatment plan. Clinicians mentioned all the above lead to high readmission rates, which drives  
227 costs up and increases pressure on healthcare systems. Comorbidities among COPD patients were  
228 also noted as an important determinant of hospitalisation, even in mild cases that otherwise would  
229 not have led to hospitalisation.



230

231 Theme 5: Limited access to specialised care

232

233 Clinicians highlighted limited access to specialised care as a significant barrier to quality COPD care.  
234 They expressed concerns about the shortage of specialists to meet the demands of the COPD patient  
235 population, resulting in long waiting times for consultations. This is linked to the over-reliance on  
236 specialists to diagnose and manage COPD patients (Theme 2). This theme did not apply to Taiwan,  
237 which has generally good access to specialist care.

238 The concentration of specialists in urban areas was identified as leaving COPD patients in smaller  
239 towns and remote locations without access to vital services. Clinicians noted that patients from rural  
240 or remote settings have to travel long distances to see a specialist. They felt this discouraged these  
241 patients from seeking care, reduced compliance, and introduced financial burdens.

242 *“It’s because the number of specialists [in the big cities] is higher than in the rest parts of Russia (sic)*  
243 *historically. I believe that patients might have access to more types of treatment in these two cities*  
244 *[Moscow and St Peterburg] compared to other parts of Russia.”* Respiratory Specialist, Russia.

245 Clinicians mentioned that the increased waiting times to see a specialist can be particularly  
246 detrimental to COPD patients because they are either not receiving any treatment or they remain on  
247 the wrong treatment regimen, leaving patients at a higher likelihood of experiencing exacerbations.

248 *“I would say if I refer the patient into our public outpatient, I would be warning the patient that it*  
249 *could be anywhere between three to six months before they’ll get seen.”* GP, Australia.

250

251 Theme 6: Insurance coverage and reimbursement challenges

252

253 This theme applies to Argentina, Mexico, and Russia.

254 Clinicians highlighted the impact of insurance coverage and reimbursement on COPD management.  
255 They observed challenges in drug reimbursement for mild and moderate COPD cases, as coverage  
256 often focuses on severe cases. In Russia, deliberate misdiagnosis (i.e. asthma) reportedly occurs to  
257 ensure reimbursement.

258 Restricted availability and affordability of medications were recognised as factors directly influencing  
259 clinical decision-making and leading to inadequate disease management. Moreover, in some

260 countries clinicians emphasised the challenges patients' face in public systems compared to private  
261 systems, and the negative impact of poor insurance coverage on access to quality COPD care.

262

### 263 Theme 7: Impact of underfinanced and overloaded healthcare systems

264

265 Clinicians identified underfinanced and overloaded healthcare systems as directly impacting the  
266 quality of COPD care. They highlighted system weaknesses that hindered timely diagnosis,  
267 comprehensive assessments, and regular monitoring of COPD patients. One example they stated is  
268 that short appointments do not allow for a thorough assessment, inhaler technique check, patient  
269 education, etc.

270 *"Usually, a physician has to do that [inhaler technique check] during the patient visit. But as far as we*  
271 *know, sometimes the physician is very pressed for time during the visit and, unfortunately, this very*  
272 *important part of the consultation is absent."*, Respiratory specialist, Russia.

273 Clinicians observed that COPD receives fewer resources within healthcare systems compared to  
274 other conditions, such as diabetes or cardiovascular diseases, indicating a need for increased  
275 attention and resource allocation. One frequently cited example was the need to have more COPD-  
276 dedicated specialist nurses.

277 *"For example, primary care has [specialised] nurses, but I think that they're not really involved with COPD*  
278 *patients, for instance. I don't know whether to call this tradition or if they are more used to following up on*  
279 *hypertensive or diabetic patients than on COPD patients."*, GP, Australia.

280 Even when the clinicians' understanding of the available treatment options is sufficient, they  
281 reported often having restrictions regarding what they can prescribe or where to refer patients.  
282 They mentioned the lack of essential services such as pulmonary rehabilitation, smoking cessation,  
283 counselling, patient education, etc. Furthermore, affordability issues were seen to push clinicians to  
284 alter treatment plans based on reimbursement options rather than guideline-based care (Theme 6).

285 The contribution of unrecognised social disparities to poor treatment outcomes among certain COPD  
286 patients was emphasised. Addressing these disparities and promoting equity in access to care were  
287 identified as crucial steps to enhance COPD management. Variations between regions, particularly in  
288 countries with extensive geographical spreads, were noted.

289

290

291 **Discussion**

292 *Main findings*

293 This research indicated that barriers to optimal care for COPD patients are very similar across all  
294 countries, with five out of the seven themes identified in this research applying to all of them:  
295 *Challenges in COPD diagnosis; Strengthening the role of primary care; Fragmented healthcare*  
296 *systems and coordination challenges; Inadequate management of COPD exacerbations; and, Impact*  
297 *of underfinanced and overloaded healthcare systems.* This finding implies that the challenges faced  
298 in delivering effective COPD care are not limited to specific countries and are shared across different  
299 contexts. The presence of similar barriers suggests that these issues are pervasive and need to be  
300 addressed globally to improve COPD management. It also highlights that COPD continues to be  
301 under-prioritised, irrespective of a country's economic development status and the resilience of its  
302 healthcare systems.

303 Only one theme (*Insurance coverage and reimbursement challenges*; Theme 6) was reportedly more  
304 relevant to the UMICs included in this study (Argentina, Mexico and Russia) and was not reported as  
305 a barrier by clinicians in HICs (Australia, Spain and Taiwan). Another difference was that Theme 5,  
306 *Limited access to specialised care*, did not apply to Taiwan, where patients have better access to  
307 specialists and have short waiting times to see them (26).

308 The development of the Evidenced Care Pathways offered a clear and concise overview of how  
309 COPD care is currently delivered across six diverse healthcare settings, depicting the complex  
310 interplay of various stakeholders, interventions, and transitions involved in the care process.

311 *Comparing the findings with previous similar work*

312 Although broadly similar, the theme structure identified in this research differs from the one  
313 reported by Meiwald et al. (14), where only four HICs were included (Canada, England, Germany and  
314 Japan). The key differences are linked to the emergence of two new themes (Themes 6 and 7) that  
315 explain how structural issues across healthcare systems affect COPD care. This difference in the  
316 theme structure emphasises the importance of including countries with less resilient healthcare  
317 systems, such as Argentina, Mexico, and Russia (27). Through this inclusive approach, this research  
318 provides a better understanding of both shared and unique challenges in COPD care in UMICs and  
319 HICs.

320 The themes identified in this study are consistent with another publication that suggests the quality  
321 standards in COPD care (28). Four out of five quality standards suggested by a panel of clinical

322 experts and patient representatives (timely diagnosis, patient awareness, availability of treatment  
323 options and adequate management of exacerbations) overlap with the themes reported here.

324 Kayyali et al. mapped and compared the COPD care delivery pathways in five European countries  
325 and, similarly to our findings, reported that most challenges were shared in all countries despite  
326 pathway variation (10). These included different manifestations of healthcare system fragmentation,  
327 which we also identified as a theme (Theme 3). Kayyali et al. emphasised the lack of a specialised  
328 role for pharmacists and informal carers (10), which the clinicians interviewed in our study did not  
329 report. However, this does not necessarily mean that these are not relevant issues in the countries  
330 we studied, but might rather reflect differences in the discussion guides.

### 331 *Interpretation of the findings*

332 Clinicians in both HICs and UMICs face similar barriers, but the scale of the problem described in  
333 each theme varies (as outlined in Tables 4-10). Our results suggest UMICs experience a higher  
334 burden of COPD and associated challenges (29).

335 Clinicians' observations revealed a notable difference in the role of exacerbations as drivers of COPD  
336 diagnosis between HICs and UMICs. In UMICs, clinicians reported that over 50% of COPD diagnoses  
337 are made following an exacerbation. In contrast, this was substantially lower in HICs (10-20%), which  
338 is consistent with other literature on exacerbations (30,31). These perspectives suggest that in  
339 UMICs, there might be an even greater delay in recognising and diagnosing COPD, which could  
340 impact timely intervention and disease management.

341 There were disparities in the perceived availability of services and treatment options for non-  
342 pharmacological therapy between HICs and UMICs. Clinicians in Spain, Australia, and Taiwan report  
343 better availability of non-pharmacological therapies than that reported by clinicians in the UMICs.  
344 However, even in these HICs, clinicians acknowledge that existing services are still inadequate to  
345 meet the needs of COPD patients. This emphasises the importance of improving non-  
346 pharmacological therapy options across all countries and is consistent with other publications  
347 (32,33).

348 Pulmonary rehabilitation was reportedly more accessible in Taiwan and Australia compared to  
349 Argentina, Mexico, and Russia, likely reflecting better infrastructure in HICs. Patient management  
350 programmes, inhaler technique education, and smoking cessation services were also reportedly  
351 more available in HICs. However, HICs and UMICs may face different challenges in these services  
352 (34).

353 Treatment availability and affordability reportedly pose greater challenges in UMICs (Argentina,  
354 Mexico, Taiwan) than in HICs (Australia, Spain). This indicates the importance of addressing  
355 affordability and expanding access to essential treatments and preventive measures in UMICs (35).  
356 Given that clinicians in Russia are deliberately misdiagnosing COPD patients with asthma so patients  
357 can get reimbursed, indicates that despite COPD's high burden, it may not receive the same  
358 prioritisation and financial support as other non-communicable diseases (NCDs) (36). This also an  
359 issue in HICs.

360 There were notable differences between public and private healthcare provision in Mexico and  
361 Argentina, manifested as stark disparities in COPD care depending on the health insurance  
362 individuals can afford. The prominent role of private healthcare was not reported in other countries.

### 363 *Strengths and limitations*

364 Interviews with clinicians from six countries facilitated a comprehensive analysis that provides a  
365 broader perspective on challenges in diverse healthcare settings. It also enabled us to compare and  
366 contrast barriers to the guideline-directed management of COPD in HICs and UMICs. To the best of  
367 our knowledge, this comparison has not been previously reported.

368 Including the graphic presentations of care pathways in the interviews facilitated meaningful  
369 discussions with clinicians, as they could see a comprehensive overview of COPD care in their  
370 respective countries when considering barriers and deviations from guidelines.

371 One limitation is that interviews occurred in different periods and by multiple researchers, which  
372 may have introduced inconsistencies in how questions were asked. Nevertheless, all researchers  
373 utilised the same discussion guides, minimising potential inconsistencies. Additionally, some  
374 interviews required interpretation and translation of the transcripts, which may have resulted in the  
375 loss of certain subtleties. However, since the analysis did not focus on nuances behind clinicians'  
376 statements, this limitation is of lesser concern.

377 Lastly, when comparing the barriers between the countries, the differences may not be attributable  
378 to real variations in care provision but rather to the information the interviewee gave. It is possible  
379 some of their views were not expressed due to a lack of probing by the interviewer.

### 380 *Policy implications*

381 The implications of our findings extend beyond this study. Policymakers can utilise the insights from  
382 the themes to identify areas where healthcare systems needs strengthening for COPD patients.  
383 Furthermore, given that most barriers are similar across healthcare settings, there are opportunities

384 for concerted efforts in COPD care through international policy initiatives. While there are many  
385 overarching strategies for NCDs generally (37), there is no coordinated strategy to encourage  
386 countries to prioritise the prevention and management of COPD (e.g., improved diagnosis through  
387 better use of spirometry and guideline-adherent therapy), which is one of the main NCDs driving up  
388 global mortality and morbidity rates (38). Similar to other NCDs, the findings of this research can  
389 inform efforts to develop funded national respiratory strategies (39,40).

390 Policymakers can leverage the visual presentation of the Evidenced Care Pathways to facilitate  
391 discussions, align goals, and encourage interdisciplinary cooperation, leading to better coordination  
392 of care, reduced fragmentation, and improved patient outcomes (41).

393 For future research, exploring approaches that further unify and systematise care pathway mapping  
394 would be valuable, ensuring academic rigour while informing policy action. The replication of the  
395 Evidenced Care Pathways in other countries could be a starting point.

## 396 **Conclusion**

397 HICs and UMICs differ regarding awareness levels among patients and HCPs, primary care  
398 involvement, spirometry access, and specialised care availability. While both face challenges related  
399 to fragmented healthcare systems, guideline adherence, and COPD exacerbation management,  
400 UMICs struggle with additional issues stemming from limited resources and healthcare  
401 infrastructure.

402 Most barriers to COPD care are similar across HICs and UMICs, indicating that COPD remains a  
403 persistent challenge. While unique issues need to be addressed through tailored approaches, there  
404 are missed opportunities to implement international respiratory strategies that encourage countries  
405 to take measures to manage COPD adequately. Alongside efforts at the healthcare system level,  
406 there is a need for political prioritisation of COPD to ensure it is allocated the necessary resources,  
407 even in HICs.

## 408 **Acknowledgements**

409 We want to thank all participants who contributed valuable insight to depict current care for COPD.  
410 Many thanks go to Alice Sinclair for coding the transcripts and Mathilde Vankelegom, Nuri Ahmed,  
411 Paddy Goddard-Watts, and Aleix Rowlandson for leading some interviews. Lastly, we would like to  
412 express our gratitude to Marta Wanat for providing her qualitative expertise to improve the design  
413 and reporting of this research.

414 **Funding**

415 Aquarius Population Health was funded by AstraZeneca to carry out this research. The study design,  
416 data gathering, data analysis, results and interpretation were carried out independently by the  
417 authors. AstraZeneca reviewed the manuscript once for medical and scientific accuracy. The authors  
418 confirm they had full access to all the data in this study and take complete responsibility for the  
419 integrity and accuracy of the analysis.

420 **Disclosure**

421 OS, AM, KPS, RGA, and EA worked at Aquarius Population Health at the time of the project. Aquarius  
422 Population Health receives consultancy and research fees from other pharmaceutical and MedTech  
423 companies unrelated to this work.

424 Abelardo Elizondo Rios has served on boards for trials sponsored by AstraZeneca, Bayern, Novartis  
425 and GSK. Alexis Cazaux has no conflict of interest in relation to the topic of this research. Outside of  
426 the submitted work, Sergey Avdeev reports receiving consulting fees and/or fees for attending  
427 lectures, meetings and conferences and/or travel expenses and/or research grants from  
428 AstraZeneca, Novartis, GSK, Teva, Sanofi, and Chiesi. Peter Wark has no conflict of interest in  
429 relation to the topic of this research.

430

431 **Author contributions**

432 All authors made a significant contribution to the work reported. RGA, KT, and EA were involved in  
433 the conception, study design, and execution. KPS was involved with the acquisition of data. OS and  
434 RGA performed the analysis and interpretation. All coauthors took part in drafting, revising or  
435 critically reviewing the article; gave final approval of the version to be published; agreed on the  
436 journal to which the article has been submitted; and agree to be accountable for all aspects of this  
437 work.

438

439

## 440 **References**

- 441 1. Buist S. COPD: A common disease that is preventable and treatable. *Prim Care Respir J J Gen*  
442 *Pract Airw Group*. 2006 Feb;15(1):7–9.
- 443 2. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease  
444 and its attributable risk factors in 204 countries and territories, 1990-2019: results from the  
445 Global Burden of Disease Study 2019. *BMJ*. 2022 Jul 27;378:e069679.
- 446 3. Quaderi SA, Hurst JR. The unmet global burden of COPD. *Glob Health Epidemiol Genomics*.  
447 2018 ed;3:e4.
- 448 4. Global strategy for the diagnosis, management, and prevention of chronic obstructive  
449 pulmonary disease (2022 Report) [Internet]. Global Initiative for Chronic Obstructive Lung  
450 Disease (GOLD); 2021 Nov [cited 2022 Aug 10] p. 77. Available from: <https://goldcopd.org/>
- 451 5. Quaderi SA, Hurst JR. The unmet global burden of COPD. *Glob Health Epidemiol Genomics*.  
452 2018 Apr 6;3:e4.
- 453 6. Preker AS, Cotlear D, Kwon S, et al. Universal health care in middle-income countries: Lessons  
454 from four countries. *J Glob Health*. 11:16004.
- 455 7. Glaab T, Banik N, Rutschmann OT, et al. National Survey of Guideline-Compliant COPD  
456 Management Among Pneumologists and Primary Care Physicians. *COPD J Chronic Obstr Pulm*  
457 *Dis*. 2006 Jan;3(3):141–8.
- 458 8. Ragaišienė G, Kibarskytė R, Gauronskaitė R, et al. Diagnosing COPD in primary care: what has  
459 real life practice got to do with guidelines? *Multidiscip Respir Med*. 2019;14:28.
- 460 9. Ruparel M, López-Campos JL, Castro-Acosta A, et al. Understanding variation in length of  
461 hospital stay for COPD exacerbation: European COPD audit. *ERJ Open Res* [Internet]. 2016 Jan  
462 1 [cited 2022 Nov 23];2(1). Available from:  
463 <https://openres.ersjournals.com/content/2/1/00034-2015>
- 464 10. Kayyali R, Odeh B, Frerichs I, et al. COPD care delivery pathways in five European Union  
465 countries: mapping and health care professionals' perceptions. *Int J Chron Obstruct Pulmon*  
466 *Dis*. 2016 Nov 14;11:2831–8.
- 467 11. Utens C, Maarse J, Schayck O van, et al. Care delivery pathways for Chronic Obstructive  
468 Pulmonary Disease in England and the Netherlands: a comparative study. *Int J Integr Care*  
469 [Internet]. 2012 May 18 [cited 2021 Apr 28];12(2). Available from:  
470 <http://www.ijic.org/articles/abstract/10.5334/ijic.811/>
- 471 12. Laue J, Melbye H, Halvorsen PA, et al. How do general practitioners implement decision-  
472 making regarding COPD patients with exacerbations? An international focus group study. *Int J*  
473 *Chron Obstruct Pulmon Dis*. 2016 Dec 8;11:3109–19.
- 474 13. Quint JK, O'Leary C, Venerus A, et al. Prescribing Pathways to Triple Therapy: A Multi-Country,  
475 Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary  
476 Disease. *Pulm Ther*. 2020 Dec;6(2):333–50.



- 477 14. Meiwald A, Gara-Adams R, Rowlandson A, et al. Qualitative Validation of COPD Evidenced Care  
478 Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care.  
479 *Int J Chron Obstruct Pulmon Dis*. 2022 Jul 1;17:1507–21.
- 480 15. Lennox L, Green S, Howe C, et al. Identifying the challenges and facilitators of implementing a  
481 COPD care bundle. *BMJ Open Respir Res*. 2014 Jun 1;1(1):e000035.
- 482 16. Young M, Villgran V, Ledgerwood C, et al. Developing a Multidisciplinary Approach to the COPD  
483 Care Pathway. *Crit Care Nurs Q*. 2021 Mar;44(1):121–7.
- 484 17. World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2023  
485 Oct 27]. Available from: [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)  
486 [world-bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 487 18. Cheng S-L, Lin C-H, Chu K-A, et al. Update on guidelines for the treatment of COPD in Taiwan  
488 using evidence and GRADE system-based recommendations. *J Formos Med Assoc Taiwan Yi*  
489 *Zhi*. 2021 Oct;120(10):1821–44.
- 490 19. México, CENETEC. Diagnóstico y Tratamiento de la Enfermedad Pulmonar Obstructiva Crónica.  
491 Guía de Práctica Clínica: Evidencias y Recomendaciones [Internet]. 2021. Available from:  
492 <http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-037-21/ER.pdf>
- 493 20. Ministerio de Salud de la Nación. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de  
494 la EPOC [Internet]. 2016 p. 156. Available from: [https://bancos.salud.gob.ar/recurso/guia-de-](https://bancos.salud.gob.ar/recurso/guia-de-practica-clinica-para-el-diagnostico-y-tratamiento-de-la-epoc)  
495 [practica-clinica-para-el-diagnostico-y-tratamiento-de-la-epoc](https://bancos.salud.gob.ar/recurso/guia-de-practica-clinica-para-el-diagnostico-y-tratamiento-de-la-epoc)
- 496 21. Russian Respiratory Society. Chronic obstructive pulmonary disease. Clinical guidelines.  
497 [Internet]. 2021. Available from: [https://www.spulmo.ru/upload/kr/HOBL\\_2021.pdf](https://www.spulmo.ru/upload/kr/HOBL_2021.pdf)
- 498 22. Soler-Cataluña JJ, Piñera P, Trigueros JA, et al. Actualización 2021 de la guía española de la  
499 EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC. *Arch*  
500 *Bronconeumol*. 2022 Feb 1;58(2):159–70.
- 501 23. Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the  
502 diagnosis and management of chronic obstructive pulmonary disease: 2017 update. *Med J*  
503 *Aust*. 2017 Nov 20;207(10):436–42.
- 504 24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a  
505 32-item checklist for interviews and focus groups. *Int J Qual Health Care J Int Soc Qual Health*  
506 *Care*. 2007 Dec;19(6):349–57.
- 507 25. Braun V, Clarke V. Reflecting on reflexive thematic analysis. *Qual Res Sport Exerc Health*. 2019  
508 Aug 8;11(4):589–97.
- 509 26. Wu T-Y, Majeed A, Kuo KN. An overview of the healthcare system in Taiwan. *Lond J Prim Care*.  
510 2010 Dec;3(2):115–9.
- 511 27. Ng M, Fullman N, Dieleman JL, et al. Effective Coverage: A Metric for Monitoring Universal  
512 Health Coverage. *PLOS Med*. 2014 Sep 22;11(9):e1001730.
- 513 28. Bhutani M, Price DB, Winders TA, et al. Quality Standard Position Statements for Health System  
514 Policy Changes in Diagnosis and Management of COPD: A Global Perspective. *Adv Ther*. 2022  
515 Jun 1;39(6):2302–22.

- 516 29. Menezes AMB, Perez-Padilla R, Jardim JB, et al. Chronic obstructive pulmonary disease in five  
517 Latin American cities (the PLATINO study): a prevalence study. *The Lancet*. 2005 Nov  
518 26;366(9500):1875–81.
- 519 30. Soler-Cataluña JJ, Izquierdo JL, Juárez Campo M, et al. Impact of COPD Exacerbations and  
520 Burden of Disease in Spain: AVOIDEX Study. *Int J Chron Obstruct Pulmon Dis*. 2023 Jun  
521 8;18:1103–14.
- 522 31. Naranjo L, Torres-Duque CA, Colodenco D, et al. Highlights of an Expert Advisory Board on  
523 Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) in Latin America. *Int  
524 J Chron Obstruct Pulmon Dis*. 2020 Aug 6;15:1919–29.
- 525 32. ur Rehman A, Hassali MAA, Abbas S, et al. Pharmacological and non-pharmacological  
526 management of COPD; limitations and future prospects: a review of current literature. *J Public  
527 Health*. 2020 Aug 1;28(4):357–66.
- 528 33. Corhay J-L, Dang DN, Van Cauwenberge H, et al. Pulmonary rehabilitation and COPD: providing  
529 patients a good environment for optimizing therapy. *Int J Chron Obstruct Pulmon Dis*.  
530 2014;9:27–39.
- 531 34. Desveaux L, Janaudis-Ferreira T, Goldstein R, et al. An International Comparison of Pulmonary  
532 Rehabilitation: A Systematic Review. *COPD J Chronic Obstr Pulm Dis*. 2015 Mar 4;12(2):144–53.
- 533 35. Jardim JR, Stirbulov R, Moreno D, et al. Respiratory medication use in primary care among  
534 COPD subjects in four Latin American countries. *Int J Tuberc Lung Dis Off J Int Union Tuberc  
535 Lung Dis*. 2017 Apr 1;21(4):458–65.
- 536 36. Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12  
537 regions of the Russian Federation. *Int J Chron Obstruct Pulmon Dis*. 2014;9:963–74.
- 538 37. Dugani S, Gaziano TA. 25 by 25: Achieving Global Reduction in Cardiovascular Mortality. *Curr  
539 Cardiol Rep*. 2016 Jan;18(1):10.
- 540 38. Halpin DMG, Celli BR, Criner GJ, et al. It is time for the world to take COPD seriously: a  
541 statement from the GOLD board of directors. *Eur Respir J [Internet]*. 2019 Jul 1 [cited 2023 Jul  
542 2];54(1). Available from: <https://erj.ersjournals.com/content/54/1/1900914>
- 543 39. Jailobaeva K, Falconer J, Loffreda G, et al. An analysis of policy and funding priorities of global  
544 actors regarding noncommunicable disease in low- and middle-income countries. *Glob Health*.  
545 2021 Jun 29;17(1):68.
- 546 40. Jackson-Morris A, Nugent R. Tailored support for national NCD policy and programme  
547 implementation: an over-looked priority. *BMJ Glob Health*. 2020 Aug 1;5(8):e002598.
- 548 41. Vargas I, Mogollón-Pérez A-S, Eguiguren P, et al. Lessons learnt from the process of designing  
549 care coordination interventions through participatory action research in public healthcare  
550 networks of six Latin American countries. *Health Res Policy Syst*. 2023 Jun 1;21(1):39.

552 **Table 1**

553

554 *Table 1. Characteristics of the research team and their connection with the relationship with the participants.*

<b>The research team and reflexivity</b>	<b>Description</b>
Interviewer/facilitator	AR, KPS, MV, NA PGW and RGA conducted the interviews.
Data analysis	AS and OS coded the transcripts.
Occupation	All researchers were employees of Aquarius Population Health at the time when the research was conducted.
Gender	AS, AR, MV, NA and OS identify as women. KPS, PGW and RGA identify as men.
Experience and training	RGA has 31 years of qualitative market research experience AS has 10 years of experience in qualitative research in academic settings. The rest of the research team had 6-12 months of experience in qualitative research when the interviews and data analysis were conducted.
Relationship established	There was no relationship between the research team and the interviewees before the interview. All participants reported they had a professional relationship with AstraZeneca.
Participant knowledge of the interviewer	The participants were informed that Aquarius Population Health would carry out the interviews. The interviewer told the participant about their background, role at Aquarius, and involvement with this research.
Interviewer characteristics	The participants were informed that Aquarius is an independent consultancy firm contracted by AstraZeneca to conduct the research. They were also told that Aquarius is responsible for the research design, data analysis and the reporting of the findings with no involvement from AstraZeneca.

555 **Abbreviations:** BA (Hons), Bachelor of Arts with Honours; MSc, Master of Science.

556

**Table 2**

*Table 2. Themes, subthemes and quotes identified from analysing 17 interview transcripts in six countries: Argentina, Australia, Mexico, Russia, Spain, and Taiwan.*

Theme	Subthemes	
<p>1. Getting a correct COPD diagnosis is potentially the biggest challenge affecting patients and healthcare systems.</p>	<ul style="list-style-type: none"> <li>1.1. There are many undiagnosed COPD patients in the population</li> <li>1.2. Low awareness about COPD means patients adapt or put up with the disease unnecessarily</li> <li>1.3. Patients take too long to present to healthcare and present with an advanced disease</li> <li>1.4. Patients have several visits before they get a diagnosis, meaning that COPD symptoms go unrecognised by physicians.</li> <li>1.5. Exacerbations are the key driver of getting a COPD diagnosis</li> </ul>	<p><i>“In my opinion, more than 50% of our patients are without this diagnosis, but they have complaints and they suffer from this disease.”</i></p> <p><i>“It’s true that they don’t get there so often because of coughing and sputum like they do from other symptoms because since they attribute coughing and sputum to tobacco use, well, they don’t usually make a consultation because of that.”</i></p> <p><i>“But I think a substantial number of patients are undiagnosed in Taiwan, because I, sometimes we see patients very advanced the COPD. They are not diagnosed before.”</i></p> <p><i>“How long does it take for the clinician to determine that the patient requires to see a pulmonologist? (...) It depends on the patient’s consultations, but usually, the patient gets referred after four or five consultations.”</i></p> <p><i>“Before that [COPD diagnosis] happens, there’s usually exacerbation already. I’d say that 60% to 70% of those who end up being diagnosed or are referred for a COPD assessment, I think, is caused</i></p>

<p>2. There are missed opportunities to strengthen the role of primary care in improving COPD care.</p>	<p>2.1. Low consideration of COPD by primary care physicians is an important barrier.</p> <p>2.2. Difficulties in differentiating COPD symptoms from other conditions, especially asthma.</p> <p>2.3. Lack of access to spirometry, inconsistent use and lack of confidence among PCPs in interpreting the results</p> <p>2.4. The COPD guidelines are not suitable for GPs.</p>	<p><i>by a previous exacerbation."</i></p> <p><i>"More or less 30, 40% of the population of COPD patients are followed more or less in primary care. But an important percentage of them are followed without a proper diagnosis perhaps only chronic cough and not the current diagnosis of COPD or chronic bronchitis."</i></p> <p><i>"So there's often a problem with diagnosis. So the diagnostic step becomes an issue sometimes, there's a lot of confusion as to whether it's asthma or COPD."</i></p> <p><i>"And due to lack of interest by the family physician in diagnosing COPD. We struggle quite a bit. We have plenty of training but there continues to exist a gap when it comes to looking for COPD."</i></p> <p><i>"(...) chest X-ray is an access study by the primary care physician. Spirometry, however, it's a resource managed usually by the pulmonologist."</i></p>
<p>3. <b>The complex nature of COPD requires good coordination between patients, PCPs and specialists, but healthcare systems are fragmented.</b></p>	<p>3.1. There are opportunities to clarify the roles of GPs and specialists in the treatment initiation and follow-up of COPD patients.</p> <p>3.2. Some clinicians display poor understanding and adherence to pharmacological treatment guidelines.</p> <p>3.3. Limited access and inconsistent use of non-pharmacological treatments.</p> <p>3.4. Poor patient compliance, adherence and self-management</p>	<p><i>"Yes. I understand that probably mild COPD must be followed by primary care. That would be an intelligent approach for the health system, but in Argentina it doesn't happen that way. Probably secondary care and especially some pulmonologists are leading the vast majority the assess and the following of the patients during the entire disease. "</i></p>

	<p>impacts treatment outcomes.</p>	<p><i>“It’s normally a specialist because primary care physicians, they don’t know many details of COPD management and dispatch patient to specialist and then they try to have their prescription and they use their prescription for treatment of patient. “</i></p> <p><i>“I think that out of 10 patients, 6 or 7 are being managed correctly and 3 aren’t.”</i></p> <p><i>“That’s typical on COPD patients. Regardless of whether it’s working or not, whether corticosteroid is causing any harm or not, whether there are exacerbations or not. No review on treatment changes. Therapeutical inertia is one of the greatest challenges with COPD. Just as that.”</i></p> <p><i>“The guidelines establish which are the patients to be rehabilitated, but many patients don’t have access because there are no rehabilitation programs set up in State-run institutions. Require trained professionals, so I’d say it’s a key limitation. Many patients that require rehabilitation don’t get it.”</i></p> <p><i>“So if I’m breathless, isn’t my cardiac failure today? Or is it the fact that I’m unwell? Because I’ve got a cold, and now I’m exacerbating my airways disease? And then look, that’s a hard thing for patients to pick up. And it’s a hard thing for doctors to pick up sometimes.”</i></p>
--	------------------------------------	--

<p>4. Healthcare systems are failing to adequately manage patients that present with COPD exacerbations.</p>	<p>4.1. Exacerbations often go unreported, reported too late and misclassified (severity).</p> <p>4.2. Patients lack the necessary education to identify and act on exacerbations.</p> <p>4.3. Not enough action plans are set up or revised following exacerbations.</p> <p>4.4. High hospitalisation and readmission rates among patients with exacerbations are driving costs up.</p> <p>4.5. The presence of comorbidities among COPD patients often becomes an important determinant for their hospitalisation.</p>	<p><i>"I think we have to improve the patient's education, make them aware about what they can do when they start exacerbating and the access the patient has to their doctors, right?"</i></p> <p><i>"Very few [COPD patients have an action plan after exacerbation]. There are lots of people who give them an action plan, but I wouldn't say that's it's been put in place as it happens with asthma patients, for example."</i></p> <p><i>"That shouldn't happen[returning with an exacerbation after 90-days from discharge] if patients are well managed, but 50% of severe patients get re-hospitalised. Patients with important damage lung get easily re-hospitalised"</i></p> <p><i>"Yeah, we've, it's, there's a bit of skulduggery with all of that [management of exacerbations in hospital], and that anyway, yes. So there's a rapid turnaround time. And unfortunately, there's also a readmission cost with that."</i></p> <p><i>"Frequently COPD patients represent 20% of pulmonology admissions in the entire year so, it turns out to be very repetitive, admission, treatment, discharge, admission..."</i></p> <p><i>"So, the criterion for admitting a patient isn't COPD only but the associated comorbidities. And actually, if we were to look over the patients we admit, a</i></p>
--	--	---

		<p><i>good number of them might not need to be admitted if they didn't have comorbidities, but since..."</i></p>
<p>5. Access to specialised care is limited and represents one of the major barriers to quality care.</p>	<p>5.1. There are not enough specialists to cover the needs of the COPD patient population.</p> <p>5.2. Specialists are usually concentrated in large urban areas, leaving COPD patients in smaller towns and remote locations without vital services.</p> <p>5.3. Long waiting times to see specialists introduce delays in getting treatment.</p> <p>5.4. Having to travel long distances to see a specialist discourages patients, reduces compliance and introduces costs.</p>	<p><i>"In that same sense, the number of pulmonologists is less than the number of patients with respiratory diseases, so there's no capacity available. A patient may need to wait for 70, 80 days so the patients get exhausted by it. The problem appears today and they'd like to get it resolved now instead than in 70 days."</i></p> <p><i>"Okay. It means, then, that there are more diagnoses in big cities because there's greater access to health services and in rural areas there are no pulmonologists and no spirometry is being done, so the diagnosis rate is low, meaning the underdiagnosis is greater."</i></p> <p><i>"It's whoever's there, and where you are, determines it [who sees the patient presenting with an exacerbation]. So all well and good to say you should come in under the care of a respiratory physician but if you've been admitted to if you've got an exacerbation of COPD, and you go to Maury hospital, it'll be one of the local general practitioners that look after you."</i></p> <p><i>"Exactly, we [respiratory physicians] are centralised. I think it's not that we're short, it's that we're not well distributed."</i></p>



		<p><i>“Certainly away from major urban centres, almost all of COPD care is carried out either by general physicians without a specific respiratory background necessarily, or primary care physicians.”</i></p>
<p>6. Insurance coverage and treatment reimbursement for COPD may become a strong limiting factor for physicians and patients.</p>	<p>6.1. Mild and moderate COPD cases struggle with drug reimbursement.</p> <p>6.2. Restricted medication availability and affordability lead to inadequate management of COPD.</p> <p>6.3. Receiving care in public systems introduces more challenges for patients than in private systems.</p> <p>6.4. Poor insurance coverage impedes access to quality COPD care.</p>	<p><i>“In Russia, the reimbursement system is quite different. For instance, in St Petersburg, patient might have medications completely reimbursed for treatment of COPD. But some parts of Russia, they reimburse if they are disabled only. Otherwise, they have to pay themselves for their treatment.”</i></p> <p><i>“The patient in private care not only has access to that medication, but also has the opportunity to have them month after month in any pharmacy. While in the public sector they depend on a single pharmacy, the one at the hospital, and at times they have to wait for the medication, and this means some days they may discontinue their therapy because they run out and they haven't been able to have new one. This has an impact in the disease control. Patients in the private sector are much better controlled than in the public sector.”</i></p>
<p>7. Underfinanced and overloaded healthcare systems directly impact the quality of care for COPD.</p>	<p>7.1. The healthcare system's weaknesses hinder timely diagnosis, comprehensive assessments, and regular monitoring.</p> <p>7.2. COPD receives fewer resources within healthcare systems compared to other conditions.</p> <p>7.3. Unrecognised social disparities contribute significantly to poor treatment outcomes.</p> <p>7.4. There are important variations in care delivery between</p>	<p><i>“Meaning the work [health education, self-management training, inhaler check], nursing does with diabetics, with hypertensive patients, nutrition and obesity. We don't even reach 20% with COPD at the national level.”</i></p> <p><i>“For example, primary care has [specialised]</i></p>

	different regions.	<i>nurses, but I think that they're not really involved with COPD patients, for instance. I don't know whether to call this tradition or if they are more used to following up on hypertensive or diabetic patients than on COPD patients."</i>
--	--------------------	---

**Table 3**

*Table 3. The variation in primary themes between countries and indications where country-specific nuances were identified at the subtheme level.*

Themes and subthemes
<b>Theme 1: Getting a correct COPD diagnosis is potentially the biggest challenge affecting patients and healthcare systems.</b>
1.1 There are many undiagnosed COPD patients in the population.
1.2 Low awareness about COPD means patients adapt or put up with the disease unnecessarily.
1.3 Patients take too long to present to healthcare and present with advanced disease.
1.4 Patients have several visits before they get a diagnosis, meaning that COPD symptoms go unrecognised by physicians.
1.5 Exacerbations are the key driver of getting a COPD diagnosis.
<b>Theme 2: There are missed opportunities to strengthen the role of primary care in improving COPD care.</b>
2.1 Low consideration of COPD by primary care physicians is an important barrier.
2.2 Difficulties in differentiating COPD symptoms from other conditions, especially asthma.
2.3 Lack of access to spirometry, inconsistent use and lack of confidence among PCPs in interpreting the results.
2.4 The COPD guidelines are not suitable for GPs.
<b>Theme 3: The complex nature of COPD requires good coordination between patients, PCPs and specialists, but healthcare systems are fragmented.</b>
3.1 There are opportunities to clarify the roles of GPs and specialists in the treatment initiation and follow-up of COPD patients.
3.2 Poor understanding and adherence to pharmacological treatment guidelines
3.3 Limited access and inconsistent use of non-pharmacological treatments.
3.4 Poor patient compliance, adherence and self-management impacts treatment outcomes.
<b>Theme 4: The complex nature of COPD requires good coordination between patients, PCPs and specialists, but healthcare systems are fragmented.</b>
4.1 Exacerbations often go unreported, reported too late and misclassified (severity).
4.2 Patients lack the necessary education to identify and act on exacerbations.
4.3 Not enough action plans are set up or revised following exacerbations.
4.4 High hospitalisation and readmission rates among patients with exacerbations are driving costs up.
4.5 The presence of comorbidities among COPD patients often becomes an important determinant for their hospitalisation.

**Theme 5: Access to specialised care is limited and represents one of the biggest barriers to quality care.**

- 5.1 There are not enough specialists to cover the needs of the COPD patient population.
- 5.2 Specialists are usually concentrated in large urban areas, leaving COPD patients in smaller towns and remote locations without vital services.
- 5.3 Long waiting times to see specialists introduce delays in getting treatment.
- 5.4 Having to travel long distances to see a specialist discourages patients, reduces compliance and introduces costs.

**Theme 6: Insurance coverage and treatment reimbursement for COPD may become a strong limiting factor for physicians and patients.**

- 6.1 Mild and moderate COPD cases struggle with drug reimbursement.
- 6.2 Restricted medication availability and affordability lead to inadequate management of COPD.
- 6.3 Receiving care in public systems introduces more challenges for patients than in private systems.
- 6.4 Poor insurance coverage impedes access to quality COPD care.

**Theme 7: Underfinanced and overloaded healthcare systems directly impact the quality of care for COPD.**

- 7.1 The healthcare system's weaknesses hinder timely diagnosis, comprehensive assessments, and regular monitoring.
- 7.2 COPD receives fewer resources within healthcare systems compared to other chronic conditions.
- 7.3 Unrecognised social disparities contribute significantly to poor treatment outcomes.
- 7.4 There are important variations in care delivery between different regions.

X

Indicates there are some country-specific nuances for the corresponding subtheme where a particular challenge or barrier for that subtheme is brought up by the clinicians.

[•]

Indicates there are some country-specific nuances for the corresponding subtheme with a positive nature where clinicians have noticed an improvement for that specific issue.



Indicates the primary theme and subthemes that do not apply to the selected countries.

## Tables 4-10

Table 4. Country-specific nuances within Theme 1, Challenges in COPD Diagnosis.

<p><b>Country-specific features:</b></p> <ul style="list-style-type: none"><li>• In Russia, Argentina, and Mexico, clinicians estimated that over 50% of COPD diagnoses are made after an exacerbation.</li><li>• In Spain, Taiwan, and Australia, clinicians thought this problem existed on a smaller scale (10-20%).</li><li>• In Russia, there was a perception that COPD prevalence is increasing due to the high prevalence of smoking across the country.</li><li>• In Argentina and Mexico, biomass was mentioned as an important risk factor for rural communities in addition to smoking.</li><li>• In Australia and Taiwan, clinicians believe that COPD awareness among patients and healthcare providers has improved in the last decade.</li></ul>
--

Table 5. Country-specific features within Theme 2, Strengthening Primary Care in COPD Care.

<p><b>Country-specific features:</b></p> <ul style="list-style-type: none"><li>• <b>In Australia</b>, clinicians mentioned the necessity to make COPD guidelines more concise for GPs.<ul style="list-style-type: none"><li>○ <i>“One of the first things I did was say we need...the concise guide. They hadn’t even thought about that GPs can’t look at a 160-page document, so that’s something.”</i>- Respiratory specialist, Australia.</li></ul></li></ul>
---

Table 6. Country-specific features within Theme 3, Fragmented healthcare systems and coordination challenges.

<ul style="list-style-type: none"><li>• <b>In Mexico</b>, clinicians mentioned many issues arising from the fact physicians attached to community pharmacies are often the first point of contact for many COPD patients. In these settings, the awareness of treatment guidelines is particularly low, and it is detrimental to patients who rely on these services due to limited access to care.<ul style="list-style-type: none"><li>○ <i>“No, they [physicians at drug stores] only prescribe salbutamol. They don’t go any further than that, they have no idea what a COPD treatment is. They don’t know what a LABA + LAMA is (...) dual therapy, triple therapy, no. They’ve never managed that in their lives.”</i> – Respiratory specialist, Mexico.</li></ul></li></ul>
---

- **In Spain and Australia**, clinicians raised concerns about a tendency to prescribe the strongest combination of treatments for COPD patients.
  - *“...all the strongest [combination of drugs] are given, and that remains the treatment for the rest of the life. No one thinks, perhaps this has been a bad year. It’s been four years since they’ve been taking this; let’s try something else, like stop or change to a milder corticoid for pneumonia prevention. No, this isn’t done. It’s an oversight.”* – Respiratory specialist, Spain.
- **In Spain and Australia**, in addition to concerns about the lack of capacity for essential services such as pulmonary rehab, clinicians perceived issues with underutilising available services from healthcare providers and patients.
  - *“But then again, we know that only about 15 to 20% of COPD admissions are referred for pulmonary rehabilitation and self-management. And sadly, only around about 10% of patients go.”*
- **In Taiwan**, clinicians mentioned a patient management programme that has introduced a more integrated care process for COPD patients.
- **In Taiwan**, there was a perception among clinicians that a national programme has helped to improve communication between hospitals and GPs.

Table 7. Country-specific features within Theme 4, Inadequate Management of COPD Exacerbations.

- **In Australia**, there was a perception that initiatives aimed at short turnaround times for patients presenting in ED with exacerbations impede the delivery of quality care. This is believed to lead to inadequate management and overlooking important steps.
  - *“So it all [discharging COPD patients with an exacerbation] happens perhaps far too quickly. And the emphasis is less on the patient and more on getting them out.”*, Respiratory specialist, Australia.
- **In Spain**, clinicians mentioned that they have a notification system for COPD exacerbations (although it operates with varying degrees of success across the country). Still, they struggle with inadequate information recording (i.e., the cause of exacerbation not recorded).
- While clinicians in Argentina, Mexico, and Russia mentioned issues with patients choosing to manage exacerbations at home, in **Australia, Spain, and Taiwan**, this was perceived to be a much smaller issue.

Table 8 - Country-specific features within Theme 5, Limited access to specialised care

- In **Taiwan**, access to specialists was perceived to be less of a problem compared to other countries.
- In **Argentina, Mexico, Russia, and Australia**, clinicians mentioned the additional financial out-of-pocket expenses that patients experience due to the travel to see a specialist.

Table 9. Country-specific features within Theme 6, Insurance coverage and reimbursement challenges

- In **Russia**, clinicians mentioned they sometimes deliberately misdiagnose patients as having asthma so they can get reimbursed for their medication. Moreover, the reimbursement policies for COPD patients vary greatly between regions, which introduces inequalities in care.
- In **Argentina and Mexico**, clinicians emphasised that there are deeper issues with drug availability in the public system, and patients often do not get the best available treatment, which exposes them to more exacerbations.
  - *“In the public sector, one can prescribe a triple therapy but not in the same pharmaceutical form. One has to divide the medication, and the patient has more triggers and inhalations to do. This has an impact on treatment complacency. We work around that for the triple therapy.”*, Respiratory specialist, Argentina.
- In **Taiwan**, GPs were reported to have limited options regarding what they can prescribe (limited reimbursed options).
  - *“The National Health Insurance Program also need to change its policies that allow the GP Doctors to do more to go follow the pharmacological prescription for COPD so their prescription can be reimbursed. Now, the reimbursement is by the policies somewhat limited.”* Respiratory Specialist, Taiwan.
- In **Russia**, clinicians highlighted the lack of access to high-quality medication as an important barrier for patients and healthcare systems.
- In **Russia, Mexico, and Argentina**, clinicians explained how they change the treatment plan based on the availability and affordability of the medications.
  - *“It does have an impact. Even for those patients with coverage, sometimes the products are too expensive, and so, I have to limit somewhat my decision [what to prescribe].”*, Respiratory specialist, Argentina.

Table 10 - Country-specific features within Theme 7, Impact of underfinanced and overloaded healthcare systems.

- In **Australia**, clinicians talked about issues with access to care for some population subgroups (i.e., indigenous communities) regardless of the country's Universal Health Coverage.
  - *“Obviously, there are some peculiarities with the Australian Health System, which has got its... it's a very good health system, we're all very lucky, we largely have access to care, we like to think it's universal care, but that's nonsense.”*, Respiratory specialist, Australia.
  - *“And that[social divide] is reflected in, in what is almost like, we're getting almost a divergent health outcomes. We see that with indigenous people. But the other elephant in the room is we also probably see that with our poorest groups of populations as well. Yeah, nobody likes talking about that.”*, Respiratory specialist, Australia.



Figure 1. Top-level presentation of the Evidenced Care Pathway. Example from the Argentinian pathway.

